Enhanced Passive Safety Surveillance of VaxigripTetra (Quadrivalent Inactivated Split Virion Influenza Vaccine, Intramuscular Route) and Efluelda (High-dose Quadrivalent Inactivated Split Virion Influenza Vaccine, Intramuscular Route) Vaccines in Europe During the Influenza Season 2022/23.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Influenza virus vaccine (Primary) ; Influenza virus vaccine (Primary)
Indications Influenza virus infections
Focus Adverse reactions
Sponsors Sanofi Pasteur

Most Recent Events

04 Jan 2023 Status changed from active, no longer recruiting to completed.
21 Nov 2022 Planned End Date changed from 7 Dec 2022 to 29 Nov 2022.
21 Nov 2022 Planned primary completion date changed from 7 Dec 2022 to 29 Nov 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight